Image courtesy of Boylston Properties

The second life science building at Arsenal Yards has secured an anchor tenant in an 11-month-old Cambridge-based biotech.

Orna Therapeutics signed a 10-year lease for 73,813 square feet at 500 Forge, a 120,000-square-foot lab building under construction at the mixed-used redevelopment.

Orna launched in February 2021 upon receiving $80 million in series A venture capital funding co-led by MPM Capital, Taiho Ventures and F2 Ventures. The firm specializes in treatments for cancer, autoimmune and genetic disorders.

Boylston Properties, The Wilder Cos. and J.P. Morgan are partners on the conversion of the Arsenal Mall property into a mixed-use development including office-lab space, a 300-unit apartment complex, retail space anchored by Roche Bros., a Majestic 7 cinema and a 146-room Hampton Inn & Suites by Hilton.

Construction on the 120,000-square-foot 500 Forge began in March 2021 with a $93 million construction loan led by a consortium of banks led by Wells Fargo. Cushman & Wakefield is leasing agent for the building, which was designed by Jacobs and built by PIDC Construction.

500 Forge features 15-to-18-foot ceiling heights, balconies and GMP-ready space on the ground floor.

Orna, which lists a current headquarters at 620 Memorial Drive in Cambridge, did not immediately respond to a request for comment. A notice of lease was filed with the Middlesex County Registry of Deeds on Jan. 4.

Arsenal Yards developers previously secured leases with SQZ Biotechnologies, Arkuda Therapeutics and Kymera Therapeutics at 200 Arsenal Yards Boulevard, a conversion of one of the Arsenal’s historic buildings.